Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Simcere Raises $65 Million by Selling its Boda Pharma Subsidiary

publication date: Jun 24, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Simcere Pharma of Nanjing agreed to sell its 99.99% stake in Jilin Boda Pharma for 400 million RMB ($65 million). Simcere bought an initial 51% ownership of Boda in 2007 for $15 million. Both Boda and Simcere produce injectible edaravone drugs that act as neuroprotectives following a stroke. The Boda sale has taken place after Simcere’s Chairman offered $503 million to take Simcere private, and the $65 million in sale proceeds will render the take-private deal easier to finance. More details....

Stock Symbol: (NYSE: SCR)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...